News

At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.

The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting.

FLF’s CMO highlights key takeaways from ASH 2024 on follicular lymphoma, from immunotherapy to new treatments.

Plain English Summary of the Publication:
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemo-immunotherapy.

Professor Jessica Okosun, FLF Scientific Advisor, answers your questions on chemotherapy-free options

Global patient survey results reveal key insights into patient perspectives on immunotherapy and information preferences

Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.

Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.

This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.

At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.

Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular

ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for

Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25

At a Glance: Bi-specific antibodies are a revolutionary form of immunotherapy recently approved for patients with relapsed or refractory Follicular Lymphoma (FL). Unlike traditional chemotherapy,

Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil

For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected

At a Glance: Clinical trials are research studies that test new treatments for Follicular Lymphoma to ensure they are safe and more effective than current

The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.